The oligonucleotide therapeutics field has seen remarkable progress over the last few years
with the approval of the first antisense drug and with promising developments in late stage …

One of the major constraints on the therapeutic use of oligonucleotides is inefficient delivery
to their sites of action in the cytosol or nucleus. Recently it has become evident that the …

VEGFR-2 is the primary regulator of angiogenesis, the development of new blood vessels
from pre-existing ones. VEGFR-2 has been hypothesized to be monomeric in the absence of …

Transcription factor TFEB is thought to control cellular functions—including in the vascular
bed—primarily via regulation of lysosomal biogenesis and autophagic flux. Here, we report …

Oncostatin M (OSM) is a pleiotropic cytokine of the interleukin (IL)‐6 family that contributes to
the progression of chronic liver disease. Here we investigated the role of OSM in the …

Angiogenesis is a complex, multistep process involving dynamic changes in endothelial cell
(EC) shapes and behaviors, especially in specialized cell types such as tip cells (with active …

Persistence of the pathology of in-stent restenosis even with the advent of drug-eluting
stents warrants the development of highly resolved in silico models. These computational …

The problem of targeted delivery of antisense and siRNA oligonucleotides can be resolved
into two distinct aspects. The first concerns devising ligand-oligonucleotide or ligand-carrier …

Vascular endothelial growth factor (VEGF) signal transduction is central to angiogenesis in
development and in pathological conditions such as cancer, retinopathy and ischemic …

The vascular endothelial growth factor (VEGF) family of cytokines are key drivers of blood
vessel growth and remodeling. These ligands act via multiple VEGF receptors (VEGFR) and …